Loading clinical trials...
Loading clinical trials...
A Multicenter, Single-Arm Phase I/II Clinical Study of the Venetoclax, Ivosidenib, and Azacitidine Triple-Drug Regimen in the Treatment of Chemotherapy-eligible Adult Patients With IDH1-Mutated Acute Myeloid Leukemia.
Conditions
Interventions
Ivosidenib, Venetoclax, Azacitidine
Locations
1
China
Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Start Date
October 17, 2025
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2028
Last Updated
February 11, 2026
NCT06973668
NCT07546435
NCT05336188
NCT06782542
NCT05613010
NCT06710548
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions